Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2016 | Research

The importance of the lepidic component as a prognostic factor in stage I pulmonary adenocarcinoma

Authors: Youngkyu Moon, Sook Whan Sung, Kyo Young Lee, Young Kyoon Kim, Jae Kil Park

Published in: World Journal of Surgical Oncology | Issue 1/2016

Abstract

Background

Stage I pulmonary adenocarcinoma (PA) can offer an unfavorable prognosis. The aim of this study was to classify the prognosis of stage I PA on the basis of the lepidic component and to confirm whether the lepidic component can be used as a criterion for predicting the prognosis of stage I PA.

Methods

We conducted a retrospective study of patients who underwent curative surgery for stage I and IIA PA. Stage I disease was divided into three groups on the basis of the lepidic component: group 1, ≤10 %; group 2, >10 to 50 %; and group 3, >50 %. We compared recurrence-free survival (RFS) rates among groups 1, 2, and 3, and stage IIA disease. We also evaluated risk factors for disease recurrence with multivariate analysis.

Results

A total of 224 patients were included in our study; most patients (n = 201) had stage I disease. Three-year RFS rates in group 1 (n = 73), group 2 (n = 75), and group 3 (n = 53) were 74.1, 90.4, and 90.0 %, respectively. There was a significant difference in RFS between group 1 and group 2 (p = 0.009). The 3-year RFS rate in stage IIA disease was 61.4 %. There were no significant differences in RFS between group 1 and stage IIA disease (p = 0.163). In multivariate analysis, group 1 had the highest risk of recurrence (HR 5.806, p = 0.006) in stage I PA.

Conclusions

Stage I PA with a lepidic component ≤10 % was associated with an unfavorable prognosis that was similar to the prognosis of stage IIA disease. The prognosis for stage I PA should not be based on general criteria, but instead, the lepidic component should be evaluated and considered when determining disease prognosis.

Parkin DM, Ferlay J, Curado MP, Bray F, Edwards B, Shin HR, et al. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer. 2010;127(12):2918–27. doi:10.1002/ijc.25517.CrossRefPubMed

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85. doi:10.1097/JTO.0b013e318206a221.PubMedCentralCrossRefPubMed

Eguchi T, Kadota K, Park BJ, Travis WD, Jones DR, Adusumilli PS. The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg. 2014;26(3):210–22. doi:10.1053/j.semtcvs.2014.09.002.PubMedCentralCrossRefPubMed

Zhang Y, Wang R, Cai D, Li Y, Pan Y, Hu H, et al. A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component. J Thorac Oncol. 2014;9(12):1772–8. doi:10.1097/JTO.0000000000000341.CrossRefPubMed

Moon Y, Kim KS, Sung SW, Lee KY, Kim YK, Kang JH, et al. Correlation of histological components with tumor invasion in pulmonary adenocarcinoma. World J Surg Oncol. 2014;12:388. doi:10.1186/1477-7819-12-388.PubMedCentralCrossRefPubMed

Kadota K, Villena-Vargas J, Yoshizawa A, Motoi N, Sima CS, Riely GJ, et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol. 2014;38(4):448–60. doi:10.1097/pas.0000000000000134.PubMedCentralCrossRefPubMed

Chao L, Yi-Sheng H, Yu C, Li-Xu Y, Xin-Lan L, Dong-Lan L, et al. Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients. Lung Cancer. 2014;86(2):164–9. doi:10.1016/j.lungcan.2014.08.018.CrossRefPubMed

Westaway DD, Toon CW, Farzin M, Sioson L, Watson N, Brady PW, et al. The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma. Pathology. 2013;45(6):553–8. doi:10.1097/PAT.0b013e32836532ae.CrossRefPubMed

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

10.

Zhang J, Wu J, Tan Q, Zhu L, Gao W. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol. 2013;8(9):1196–202. doi:10.1097/JTO.0b013e31829f09a7.CrossRefPubMed

11.

Sumiyoshi S, Yoshizawa A, Sonobe M, Kobayashi M, Fujimoto M, Tsuruyama T, et al. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages. Lung Cancer. 2013;81(1):53–9. doi:10.1016/j.lungcan.2013.04.003.CrossRefPubMed

12.

Zhang J, Liang Z, Gao J, Luo Y, Liu T. Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis. Histopathology. 2011;59(6):1204–14. doi:10.1111/j.1365-2559.2011.04050.x.CrossRefPubMed

13.

Suzuki M, Yoshida S, Tamura H, Wada H, Moriya Y, Hoshino H, et al. Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers. Eur J Cardiothorac Surg. 2009;36(6):1031–6. doi:10.1016/j.ejcts.2009.06.025.CrossRefPubMed

14.

Kameyama K, Takahashi M, Ohata K, Igai H, Yamashina A, Matsuoka T, et al. Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution. J Thorac Cardiovasc Surg. 2009;137(5):1180–4. doi:10.1016/j.jtcvs.2008.09.030.CrossRefPubMed

15.

Fibla JJ, Cassivi SD, Decker PA, Allen MS, Darling GE, Landreneau RJ, et al. Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030). Eur J Cardiothorac Surg. 2013;43(5):911–4. doi:10.1093/ejcts/ezs520.CrossRefPubMed

16.

Nentwich MF, Bohn BA, Uzunoglu FG, Reeh M, Quaas A, Grob TJ, et al. Lymphatic invasion predicts survival in patients with early node-negative non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146(4):781–7. doi:10.1016/j.jtcvs.2013.04.037.CrossRefPubMed

17.

Mimae T, Tsutani Y, Miyata Y, Yoshiya T, Ibuki Y, Kushitani K, et al. Role of lymphatic invasion in the prognosis of patients with clinical node-negative and pathologic node-positive lung adenocarcinoma. J Thorac Cardiovasc Surg. 2014;147(6):1820–6. doi:10.1016/j.jtcvs.2013.11.050.CrossRefPubMed

18.

Funai K, Sugimura H, Morita T, Shundo Y, Shimizu K, Shiiya N. Lymphatic vessel invasion is a significant prognostic indicator in stage IA lung adenocarcinoma. Ann Surg Oncol. 2011;18(10):2968–72. doi:10.1245/s10434-011-1729-9.CrossRefPubMed

19.

Ruffini E, Asioli S, Filosso PL, Buffoni L, Bruna MC, Mossetti C, et al. Significance of the presence of microscopic vascular invasion after complete resection of Stage I-II pT1-T2N0 non-small cell lung cancer and its relation with T-Size categories: did the 2009 7th edition of the TNM staging system miss something? J Thorac Oncol. 2011;6(2):319–26. doi:10.1097/JTO.0b013e3182011f70.CrossRefPubMed

20.

Nitadori J, Bograd AJ, Morales EA, Rizk NP, Dunphy MP, Sima CS, et al. Preoperative consolidation-to-tumor ratio and SUVmax stratify the risk of recurrence in patients undergoing limited resection for lung adenocarcinoma ≤2 cm. Ann Surg Oncol. 2013;20(13):4282–8. doi:10.1245/s10434-013-3212-2.PubMedCentralCrossRefPubMed

21.

Tremblay L, Deslauriers J. What is the most practical, optimal, and cost effective method for performing follow-up after lung cancer surgery, and by whom should it be done? Thorac Surg Clin. 2013;23(3):429–36. doi:10.1016/j.thorsurg.2013.05.010.CrossRefPubMed

22.

Yeh YC, Wu YC, Chen CY, Wang LS, Hsu WH, Chou TY. Stromal invasion and micropapillary pattern in 212 consecutive surgically resected stage I lung adenocarcinomas: histopathological categories for prognosis prediction. J Clin Pathol. 2012;65(10):910–8. doi:10.1136/jclinpath-2012-200882.CrossRefPubMed

23.

Woo T, Okudela K, Mitsui H, Tajiri M, Yamamoto T, Rino Y, et al. Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. Pathol Int. 2012;62(12):785–91. doi:10.1111/pin.12016.CrossRefPubMed

24.

Hung JJ, Jeng WJ, Chou TY, Hsu WH, Wu KJ, Huang BS, et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg. 2013;258(6):1079–86. doi:10.1097/SLA.0b013e31828920c0.CrossRefPubMed

25.

Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients—based on a hospital study in China. Eur J Surg Oncol. 2013;39(11):1262–8. doi:10.1016/j.ejso.2013.08.026.CrossRefPubMed

26.

Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol. 2013;8(5):612–8. doi:10.1097/JTO.0b013e318287c3eb.CrossRefPubMed

27.

Ito M, Miyata Y, Kushitani K, Yoshiya T, Mimae T, Ibuki Y, et al. Prediction for prognosis of resected pT1a-1bN0M0 adenocarcinoma based on tumor size and histological status: relationship of TNM and IASLC/ATS/ERS classifications. Lung Cancer. 2014;85(2):270–5. doi:10.1016/j.lungcan.2014.05.014.CrossRefPubMed

Title: The importance of the lepidic component as a prognostic factor in stage I pulmonary adenocarcinoma
Authors: Youngkyu Moon
Sook Whan Sung
Kyo Young Lee
Young Kyoon Kim
Jae Kil Park
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2016
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-016-0791-y

At a glance: The STEP trials

Springer Medicine

The importance of the lepidic component as a prognostic factor in stage I pulmonary adenocarcinoma

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Downregulation of selenium-binding protein 1 is associated with poor prognosis in lung squamous cell carcinoma

Preoperative endoscopic localization of colorectal cancer and tracing lymph nodes by using carbon nanoparticles in laparoscopy

Surgical outcomes of robotic thyroidectomy vs. conventional open thyroidectomy for papillary thyroid carcinoma

Palliative treatment of pelvic bone tumors using radioiodine (125I) brachytherapy

Severe Fournier’s gangrene in a patient with rectal cancer: case report and literature review

A case of peritoneal metastasis during treatment for hypopharyngeal squamous cell carcinoma